A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells
Open Access
- 1 March 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 6 (3), 1062-1069
- https://doi.org/10.1158/1535-7163.mct-06-0541
Abstract
Targeting the ubiquitin-proteasome degradation pathway has become a promising approach for cancer therapy. Previous studies have shown that proteasome inhibition leads to apoptosis in various cancer cells. The mechanism by which apoptosis occurs are not fully understood and can be cell type and/or inhibitor specific. In this study, we investigated the mechanism of mitochondrial activation by proteasome inhibitors in colon cancer cells. We found that Bax activation and mitochondria translocation were required for apoptosis induced by multiple proteasome inhibitors. In contrast, reactive oxygen species did not seem to be induced by MG132 or bortezomib and antioxidants had no effects on MG132-induced apoptosis. In contrast, treatment with MG132 or bortezomib induced a significant accumulation of p53 and PUMA. Genetic deletion of either p53 or PUMA led to a marked suppression of apoptosis induced by these inhibitors, accompanied with reduced Bax activation and cytochrome c release. Consistently, inhibition of translation by cycloheximide could also effectively abolish the accumulation of p53 and PUMA and suppress MG132-induced Bax activation and apoptosis. These findings thus strongly indicate the critical involvement of p53-, PUMA-, and Bax-mediated mitochondrial activation in proteasome inhibitor–induced apoptosis in colon cancer cells. [Mol Cancer Ther 2007;6(3):1062–9]Keywords
Other Versions
This publication has 33 references indexed in Scilit:
- Enhanced Killing of Melanoma Cells by Simultaneously Targeting Mcl-1 and NOXACancer Research, 2006
- The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 statusBlood, 2006
- A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibCancer Cell, 2005
- PROTEASOME INHIBITION IN MULTIPLE MYELOMA: Therapeutic ImplicationAnnual Review of Pharmacology and Toxicology, 2005
- Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosisBlood, 2005
- Proteasome Inhibitor PS-341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in Head and Neck Squamous Cell Carcinoma CellsMolecular and Cellular Biology, 2004
- Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and ApoptosisScience, 2004
- Cell DeathCell, 2004
- JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) CellsJournal of Biological Chemistry, 2003
- Regulation of p53 stability by Mdm2Nature, 1997